Disclosed is the use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid alone or a pharmaceutically acceptable salt thereof alone in the manufacture of a medicament for the treatment of prostate enlargement such as benign prostatic hyperplasia in a male mammal.
